Alicia Katherine Morgans MD , MPH

Genitourinary Oncology

Associate Professor of Medicine, Harvard Medical School Director, Adult Survivorship Program, Dana-Farber Cancer Institute

Join to view full profile

450 Brookline AveBoston, MA 02215
Phone+1 617-632-2698
Fax+1 617-632-2165

Dr. Morgans is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Morgans' full profile Already have an account?

Summary

Alicia Morgans, MD, MPH, FASCO is an oncology specialist based in Boston, MA, with a subspecialty in genitourinary oncology. She completed her fellowship in Hematology and Medical Oncology at Dana-Farber Cancer Institute/Mass General Brigham and her residency in Internal Medicine at the University of Pennsylvania Health System. She holds an MPH from Vanderbilt University and a BS in Biology and Spanish from Ursinus College. Dr. Morgans is currently an Associate Professor at Harvard Medical School and is the Director of the Adult Survivorship Program at Dana-Farber Cancer Institute. Her research and clinical expertise focus on prostate cancer, and she has published extensively. She has been involved in clinical trials focusing on therapies for prostate cancer, as well as studies investigating the complications of prostate cancer treatment and the quality of life of prostate cancer survivors. She has served on guidelines committees for the American Urologic Association, American Heart Association, and American Society of Clinical Oncology.

Education & Training

Vanderbilt University School of MedicineMPH, Epidemiology, 2013 - 2015
Vanderbilt UniversityMPH, 2013 - 2015
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2012
University of Pennsylvania Health SystemResidency, Internal Medicine, 2006 - 2009
Perelman School of Medicine at the University of PennsylvaniaClass of 2006

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 2009 - 2028
RI State Medical License 2022 - 2028
IL State Medical License 2017 - 2023
TN State Medical License 2012 - 2018
PA State Medical License 2006 - 2009
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification StarPanel, Vanderbilt University, 2014-2017
CMS Meaningful Use Stage 2 Certification StarPanel, Vanderbilt University, 2014-2017
CMS Meaningful Use Stage 2 Certification BI-Clinical, CitiusTech, Inc., 2014-2017

Clinical Trials

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
COMPLETED
PHASE2
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Start of enrollment: 2017 Mar 31
ACTIVE_NOT_RECRUITING
PHASE4
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study Start of enrollment: 2021 Mar 01
ACTIVE_NOT_RECRUITING
PHASE3

Publications & Presentations

PubMed

Recruitment strategies in the PROMISE Registry: Evaluating institutional outreach, direct-to-patient marketing, and community engagement approaches in a decentralized ...
Channing J Paller, Ken Freitas, Natalie Macario, Christina Tran, Kelly Faville
Contemporary Clinical Trials Communications. 2026-10-01
1 citations
Efficacy and safety of treatments for metastatic castration-sensitive prostate cancer: A comprehensive network meta-analysis including final ARANOTE data.
Neal Shore, Alicia K Morgans, Noman Paracha, Elaine Gallagher, Howard Thom
Prostate Cancer and Prostatic Diseases. 2026-09-01
Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III A...
Karim Fizazi, Matthew R Smith, Maha Hussain, Fred Saad, Cora N Sternberg
European Journal of Cancer. 2026-08-26

Journal Articles

Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from 'castration-resistant' prostate cancer
Pezaro CJ, Omlin A, Mastris K, ANZUP Consumer Advisory Panel, Attard G, Beer TM, Chi KN, Chowdhury S, Davis ID, Drake CG, de Bono JS, Efstathiou E, Gravis G, Higano CS..., Ann Oncol, 1/1/2017
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Kanz BA, Pollack MH, Johnpulle RA, Puzanov I, Horn L, Morgans AK, Sosman JA, Rapisuwon S, Conry RM, Eroglu Z, Johnson DB, Journal for ImmunoTherapy of Cancer, 1/1/2016
Optimal management of muscle-invasive bladder cancer - a review
Scarpato KR, Morgans AK, Moses KA, Res Rep Urol, 1/1/2015

Books/Book Chapters

Am Soc Clin Oncol Educ Book
Chapter: Screening and treating prostate cancer in the older patient: decision making across the clinical spectrum.
Page 370 - 381Morgans AK, Dale W, Briganti A2017
Management of Prostate Cancer
Chapter: Pitfalls of Androgen Deprivation Therapy.
Page 379 - 400Morgans AK and Smith MREditors: Klein E, Jones JS.Humana Press, NJEdition 3rd,2013
Adult Acute Lymphocytic Leukemia
Chapter: The Generalized Care of the Patient with Acute Lymphoblastic Leukemia
Page 97 - 114Mato AR, Morgans AK, Luger SMEditors: Advani AS and Lazarus HM.Humana Press, NJ2011

Abstracts/Posters

Anti-Tumor Activity, Safety and Pharmacokinetics (PK) of AGS15E (ASG-15ME) in a Phase I Dose Escalation Trial in Patients (Pts) with Metastatic Urothelial Cancer (mUC).
D.P. Petrylak, E.I. Heath, G. Sonpavde, S. George, A. Morgans, B. Eigl, J. Picus, S. Cheng, S. Hotte, E. Gartner, M. Vincent, R. Chu, B. Anand, K. Morrison, L. Jackson..., American Society of Clinical Oncology Annual Meeting, 1/1/2016
Quality of life (QOL) analysis from CHAARTED: Chemohormonal androgen ablation randomized trial in prostate cancer (E3805).
Patrick-Miller LJ, Chen YH, Carducci MA, Cella D, DiPaola RS, Gartrell BA, Jarrard DF, Liu G, Morgans AK, Wong YN, Sweeney C, American Society of Clinical Oncology Annual Meeting, 1/1/2016
Education practices in prostate cancer: A comparison of patient and caregiver experiences.
Allen JC, Du L, Ahmed IA, Morgans AK, Cancer Survivorship Symposium: Advancing Care and Research-A Primary Care and Oncology Symposium, 1/1/2016

Lectures

Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving checkpoint inhibitor (CPI) monotherapy in a US c...
2019 ASCO Annual Meeting - 6/1/2019
Biochemical Recurrence: Judicious Clinical Management of an Evolving Disease State.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Optimizing Patient-Centered Care and Follow-up in Prostate Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Authored Content

Prostate Cancer Survivorship Today: Support That Spans the Journey - Alicia MorgansJune 2023
Decision Analysis Defining Optimal Management of Clinical Stage 1 High-Risk Nonseminomatous Germ Cell Testicular Cancer with Lymphovascular InvasionMay 2018

Press Mentions

Head-to-Head on Headspace: Cognitive Effects of Darolutamide vs Enzalutamide in Advanced Prostate CancerMay 21st, 2026
Clinically Localized Prostate Cancer: AUA/ASTRO Guideline (2026)August 15th, 2025
ASCO 2025: Phase III ARANOTE Post-Hoc Analyses Presented on Health-Related Quality of Life and Pain Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving NUBEQA® (Darolutamide) plus ADTMay 27th, 2025